Background: A predictive model that identifies patients at risk of excessive neutropenia following chemotherapy would be valuable in guiding the use of supportive therapies.
introduction Myelosuppression, particularly neutropenia, is the most common toxicity seen in patients undergoing systemic cancer chemotherapy. In addition to predisposing to life-threatening infections, it often leads to treatment delays and dose reductions that reduce the intensity of chemotherapy. The importance of chemotherapy dose intensity for survival with adjuvant therapy in breast cancer is being increasingly recognised [1] [2] [3] . It appears from these studies that lower dose intensity is associated with reduced clinical benefit. There may even be a threshold level of dose intensity below which patients derive no advantage from treatment [1] . Patterns of care studies have shown that, for patients treated outside clinical trials, the schedule of chemotherapy is frequently interrupted due to haematological toxicity [4] [5] [6] . Identifying individuals who are at risk of significant myelosuppression is therefore of considerable importance to medical oncologists treating patients with breast cancer. A predictive instrument that could quantify the risk of neutropenic events (NEs) might be valuable in helping to reduce the complications arising from myelosuppression [6] [7] [8] [9] . The focus of much of the research in this area has been to better target supportive strategies and thereby avoid either serious infections or compromised dose intensity. However, previous studies are potentially confounded by the multiple chemotherapy regimens employed, different thresholds for treatment delay, a priori dose reductions, failure to discriminate between haematological and nonhaematological toxicity and variable use of myeloid growth factor support. We have analysed a large cohort of breast cancer patients treated with a single-chemotherapy regimen that is not confounded by these aforementioned factors. Previously we have reported that obesity and high body surface area (BSA) are not associated with increased myelosuppression in this group [10] . The present study describes the development of a simple model, based on pretreatment laboratory haematology values, which can be used to identify groups of patients who are at increased risk of chemotherapy-associated neutropenia.
patients and methods
Using our patient management information system, an electronic database through which chemotherapy is prescribed, we identified all patients treated with FEC chemotherapy for breast cancer in the period 2001-2005. The regimen employed (5-fluorouracil 600 mg/m 2 , epirubicin 60 mg/m 2 , cyclophosphamide 600 mg/m 2 administered i.v. every 3 weeks) has been reported previously [11] . A total of 741 patients received neo-adjuvant or adjuvant FEC. All patients were planned to receive a minimum of six cycles of treatment. Neither a priori dose reductions nor BSA capping were employed for any of the patients. A dose-banding algorithm was used to facilitate the reconstitution of drugs in our cytotoxic pharmacy. The actual doses prescribed were within 5% of the calculated doses based on BSA. Throughout the period of this audit, an institutional policy for the prescription of chemotherapy was in operation. Automated full blood counts were carried out on the day of chemotherapy. Each cycle of treatment was delivered if the absolute neutrophil count (ANC) was ‡1.5 · 10 9 /l and the platelet count ‡100 · 10 9 /l. If not, chemotherapy was delayed for 1 week. If chemotherapy had to be delayed on two occasions due to inadequate blood counts, a dose reduction of 20% was made for all agents and maintained for the rest of the treatment course. Greater dose reductions were instituted if the patient experienced further myelosuppression despite these modifications. The Gloucestershire Oncology Centre operates a 24-h telephone helpline and a dedicated neutropenic ward for the admission of all patients with febrile neutropenia (FN). After an episode of FN, doses were also reduced by 20%. Due to funding restrictions, granulocyte colony-stimulating factors (G-CSFs) were not employed as either primary or secondary prophylaxis during the period of this audit. No patient received concomitant radiotherapy and endocrine treatment was only commenced after completion of chemotherapy.
This retrospective study was approved by the departmental research and audit committee. The actual doses delivered, timing of each cycle and occurrence of FN were obtained for each patient by searching the electronic database. In any case where there was a dose reduction or cycle delay, the oncology records were reviewed to determine the cause for the alteration in treatment schedule.
A NE was defined as either an episode of FN or a dose delay ‡1 week caused by prolonged myelosuppression. Dose intensity was defined as (dose received/dose planned)/(overall treatment time/planned treatment time) over six cycles of treatment [12] . This was considered to be suboptimal if it fell <0.85 (DI < 85%) [1] .
Group comparisons for continuous blood count variables were carried out using Student's t-test. Chi-square tests were used to determine the significance of differences between categorical variables. All tests of significance were two tailed. Statistical analyses were carried out using SPSS version 10.0 (SPSS, Chicago, IL).
results
In total, 741 consecutively treated patients were identified by this retrospective study. Three hundred and twenty-five patients had a schedule interruption. The cause for this was defined as haematological in 192, non-haematological in 59, social in 15, unrelated medical conditions in 18, progressive disease in seven, patient request in seven or combined in 27. Eight patients had no retrievable blood counts. As we were interested in determining whether pretreatment blood count parameters predict for future myelotoxicity, we excluded those 141 patients with non-haematological toxicity or absent blood counts. The mean dose intensity for the remaining 600 patients was 94.6%. Of the 192 patients with a NE, 53 had an episode of FN (three patients had two episodes) and 160 experienced one or more treatment delays due to myelosuppression. In total, 104 (17.3%) patients received a DI <85% and 10 (1.6%) received a DI <65% due to myelosuppression. Patient demographics, tumour characteristics and pretreatment haematological values for this group are shown in Table 1 . Figure 1 shows the pattern of NEs over the six-cycle course of chemotherapy. While treatment delays were evenly spread throughout the course of chemotherapy, FN was more common in cycle 1 (25 of 53, 47%). Of relevance to the use of secondary G-CSF prophylaxis is the fact that 83% of patients who develop a NE in cycle 1 go onto receive a DI <85%. Importantly, however, delay of a previous cycle does not seem to correlate with the risk of subsequent FN. Of the 29 patients with FN in cycles 2-6, only two (7%) had experienced a previous treatment delay due to protracted myelosuppression ( Figure 1 ). In total, 100 patients had a 20% dose reduction following either two or more delays or an episode of FN. This was only of limited effectiveness in preventing subsequent events as 47 (47%) went on to develop a further NE despite this reduction in chemotherapy doses. Table 2 summarises the association between pretreatment haematological parameters and excessive neutropenia. Total white cell count (WCC), ANC and absolute lymphocyte count (ALC) are all associated with NEs, DI <85% and FN. Although the differences in blood count indices are statistically highly significant, their absolute values are small ( Figure 2 ). Figure 3 shows receiver-operator characteristic curves for ANC and ALC with relation to any NE and DI <85% and FN.
As ANC and ALC were both correlated with the total WCC (r = 0.91 and 0.55, respectively), but less well correlated with each other (r = 0.21), these two parameters were selected for further study. To develop a simple risk model, patients were divided into quintiles based on both ANC and ALC. These were Table 3 and Figure 4 . There were highly significant differences in the risk of NEs between these separate groups. The risk of any NE varied by 2.8-fold, DI <85% varied by 4-fold and FN by 5.3-fold between the separate groups ( Table 3 ). The distribution of NEs with relation to ANC and ALC is best appreciated in the scatter plots ( Figure 4) . One of the most striking features of Figure 4 is the low risk of significant myelosuppression in patients with higher WCCs. Thus, it is possible to define a subset of group I on the basis of patients with both an ANC >5.3 and an ALC >2.5. This group, comprising 6% of the total population, have an extremely low risk of NE (11%), DI >85% (3%) and FN (0%).
discussion
Myelosuppression and its associated complications are the most significant morbidities encountered by patients undergoing chemotherapy for breast cancer. In addition to the risks of infection, neutropenia may result in schedule alteration, reducing the intensity of treatment. In contrast to the maximum grade of haematological toxicity, the dose intensity of chemotherapy is inconsistently reported in publications of trial results. However, a survey of oncology practices found that 56% of patients treated in community hospitals received <85% of the planned dose intensity [6] . This reflects the difference between the highly selected population eligible for clinical studies and the majority of patients not treated in trials, who are generally less healthy. As chemotherapy regimens become increasingly dose intense, schedule interruptions in this wider group of patients might potentially offset the beneficial effects of more effective agents. This retrospective audit has provided some insight into the risk and timing of neutropenic complications. The FEC regimen employed has a low risk of causing FN so, using existing guidelines, primary G-CSF prophylaxis would not be indicated [13, 14] . Notwithstanding this, a large number of patients (26%) had schedule interruptions due to haematological toxicity. Furthermore, dose reductions were A large number of patients who had a NE in cycle 1 went on to receive a DI <85%. This is an important observation for guiding the use of secondary G-CSF prophylaxis. If secondary prophylaxis was completely effective at preventing subsequent NEs, then 61% of the cases of suboptimal dose intensity could be prevented by the targeted use of G-CSF based on cycle 1 NEs. This hypothesis is being tested by a randomised study conducted in UK (Anglo Celtic III) that has now completed accrual.
Previous studies have shown that chemotherapy progressively depletes the stem-cell pool in the bone marrow [15] . This is usually manifested as a reduction in white blood cell counts with each successive cycle of chemotherapy. However, it is noteworthy that of the 192 patients who had 
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a NE in our study, the majority of these could be identified after just two cycles (Figure 1) . Thus, intrinsic chemosensitivity rather than a cumulative toxicity appears to be more important in the development of NEs. It is also evident from Figure 1 that many patients who develop FN in cycles 2-6 have no forewarning of this such as delays of preceding cycles. This observation supports the hypothesis that episodes of FN result from chance infection in a susceptible window, rather than extreme or prolonged neutropenia as seems to be the case in acute leukaemia [16] . In support of this finding, a previous study, which employed selective administration of G-CSF on the basis of first cycle nadir counts, found that this strategy reduced treatment delays but had no effect on the risk of developing FN [17] .
In common with previous reports [18] , we found that episodes of FN were more frequent in cycle 1 (Figure 1 ). A simple model that quantifies the risks of NE prospectively would therefore be of clinical value for guiding the selective use of primary prophylaxis strategies. Several studies have identified patient-related factors that predispose to either FN [13, 14] or excessive myelosuppression [6] . These include age >65, advanced disease, anaemia, poor performance status, prior treatment, combined chemoradiotherapy, bone marrow infiltration and medical comorbidity particularly renal disease. However, many of these pretreatment risk factors were identified in reports which included patients with haematological malignancies and are of questionable relevance to the adjuvant treatment of breast cancer. Other studies have shown that first cycle ANC nadir can be used to predict for subsequent NE [7] [8] [9] . For example, Sibler et al. [7] studied 95 patients receiving standard-dose adjuvant chemotherapy and found that the depth of the first cycle ANC nadir was a reliable predictor of NE. However, as true nadir counts are difficult to obtain reliably and inconvenient for the patient, they are not routinely carried out in clinical practice. Our data have shown that pretreatment haematological laboratory values can also be used to predict either the risk of NE, receiving a DI <85%, or FN in patients treated with FEC. Patients with lower absolute lymphocyte and neutrophil counts are more likely to experience treatment delays or FN during their chemotherapy programme (Figures 2 and 4) . By combining the two principal component of total WCC (ANC and ALC), we developed a simple instrument which can be used to predict for susceptibility to excessive myelosuppression with FEC chemotherapy. Patients in the highest risk group, defined as ANC £3.1 and ALC £1.5, comprise 6% of the total population. They have a risk of FN (21%) that is over five-fold greater than patients in the lowest risk group. Importantly, patients in this group would qualify for G-CSF support according to current guidelines even though the overall risk of FN with the FEC regimen employed is low (7%) [13, 14] .
Why do pretreatment haematological indices, particularly the lymphocyte count, affect the risk of NE? Low WCCs might indicate bone marrow insufficiency but this would seem unlikely in this cohort of predominantly middle-aged women undergoing adjuvant chemotherapy. Previous studies have shown that granulopoiesis and B lymphopoiesis share a common developmental niche in the bone marrow, competing for critical growth and retention factors such as the chemokine SDF-1 [19] . Lower blood B lymphocyte and neutrophil counts may both result from relatively high bone marrow concentrations of SDF-1 that promotes retention of these cells in the marrow. During inflammation, it has been shown that G-CSF mobilises neutrophils and myeloid progenitors to the peripheral circulation by disrupting this SDF-1 retention signal. However, endogenous G-CSF is also required for granulopoiesis postchemotherapy and therefore may be present in limiting amounts. It is possible that the increased susceptibility of patients with lower lymphocyte and neutrophil blood counts to chemotherapy induced neutropenia may be explained by a relative increase in bone marrow SDF-1 levels in these patients coupled with limiting amounts of G-CSF following treatment. Further studies are required to test this hypothesis.
Can our findings be applied to other chemotherapy regimens? The FEC60 regimen employed for the duration of this audit is now considered to be inferior to more dose-intense regimens such as FEC100 and consequently it is less frequently used [20] . In addition, G-CSF is now more widely administered to maintain chemotherapy dose intensity in patients who have treatment delays or episodes of FN. Undoubtedly, many of the patients who received dose delays or dose reductions would currently be treated with G-CSF. Notwithstanding these reservations, the approach that we describe might prove useful with other regimens. On the basis of the current guidelines, primary prophylaxis with G-CSF is indicated when the risk of FN exceeds 20%. Although many adjuvant breast cancer regimens such as FEC100 are more ANC, absolute neutrophil count; ALC, absolute lymphocyte count; NE, neutropenic event; DI, dose intensity; FN, febrile neutropenia. Patients were divided into quintiles based on both pretreatment ANC and ALC. These were combined according to rank order. For example, group IV comprises patients with ANC £3.8 and ALC £1.8 who do not fulfil the criteria for inclusion in group V. There were statistically significant differences between the groups for any NE (P < 0.001), DI <85% (P < 0.001) and FN (P = 0.002).
original article Annals of Oncology myelosuppressive than FEC60, they still have a risk of FN <20%. We predict that patients in group V of our model will also be at >20% risk of FN with these protocols and therefore should also be considered for primary prophylaxis with G-CSF.
In conclusion, we present a simple model which provides a means of identifying a group of patients at increased risk of significant neutropenia with adjuvant FEC chemotherapy. Clearly, it will require validation in a separate dataset and we are currently working to confirm these observations with other chemotherapy regimens and disease sites. Potentially this approach will allow prophylactic G-CSF or antibiotic therapy to be targeted more effectively to patients at the highest risk of FN on the basis of the chemotherapy regimen and pretreatment laboratory parameters.
acknowledgements
